

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Vignina 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/869,696	10/31/2001	Donald Davies	2190/49927	8654
23911 7	7590 06/25/2003			
CROWELL & MORING LLP INTELLECTUAL PROPERTY GROUP P.O. BOX 14300			EXAMINER	
			KATCHEVES, KONSTANTINA T	
WASHINGTON, DC 20044-4300			ART UNIT	PAPER NUMBER
			1636	8
			DATE MAILED: 06/25/2003	-

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-326 (Rev.	04-01) Office Action	on Summary	Part of Paper No. 8		
Notice Inform S. Patent and Train		5) No	erview Summary (PTO-413) Paper No(s) tice of Informal Patent Application (PTO-152) er:		
Attachment(•	🗂			
15)∐ A	cknowledgment is made of a claim for domestic	priority under 35 L	J.S.C. §§ 120 and/or 121.		
_ a)	☐ The translation of the foreign language provi	isional application	has been received.		
	cknowledgment is made of a claim for domestic				
* Se	application from the International Bure ee the attached detailed Office action for a list o	eau (PCT Rule 17.2	?(a))		
!	3. Copies of the certified copies of the priorit	y documents have	been received in this National Stage		
:	2. Certified copies of the priority documents				
	1.☐ Certified copies of the priority documents	have been receive	rd.		
	☐ All b)☐ Some * c)☐ None of:	,,	3 (() () () () .		
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
l .	nder 35 U.S.C. §§ 119 and 120				
12)□ Т	The oath or declaration is objected to by the Exa		-		
, —	If approved, corrected drawings are required in repl				
11) 🔲 7	The proposed drawing correction filed on				
,	Applicant may not request that any objection to the				
	The drawing(s) filed on is/are: a) accept		to by the Evenine		
	The specification is objected to by the Examiner.				
	Claim(s) <u>41-85</u> are subject to restriction and/or on Papers	election requireme	nt.		
<u> </u>	Claim(s) is/are objected to.				
	Claim(s) is/are rejected.				
	Claim(s) is/are allowed.				
	4a) Of the above claim(s) is/are withdraw	n from considerati	on.		
i	Claim(s) 41-85 is/are pending in the application				
1	on of Claims				
,_	Since this application is in condition for allowa closed in accordance with the practice under <i>L</i>	nce except for fom E <i>x parte Quayl</i> e, 19	nal matters, prosecution as to the merits is 935 C.D. 11, 453 O.G. 213.		
2a)□ 3)□		s action is non-fina			
1)□ 2a)□	Responsive to communication(s) filed on				
_	Popponius to assessment of the state of				
- Exte after - If the - If NC - Failu - Any I	MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	within the statutory miniming within the statutory miniming will expire SIX cause the application to be	um of thirty (30) days will be considered timely. ((6) MONTHS from the mailing date of this communication		
A SH	ORTENED STATUTORY PERIOD FOR REPLY	IS SET TO EXPI	RE <u>3</u> MONTH(S) FROM		
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover s	neet with the correspondence address		
-	The MAN INC DATE And	Konstantina Katch	1,000		
Office Action Summary		Examiner	Art Unit		
		09/869,696	DAVIES, DONALD		
		Application No.	Applicant(s)		

Application/Control Number: 09/869,696

Art Unit: 1636

DETAILED ACTION

Claims 41-85 are pending in the present application.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 41-62, drawn to a method for treating cancer comprising administering a vector and acetominophen, classified in class 514, subclass 44.
- II. Claims 63-82 and 84, drawn to a composition, classified in class 514, subclass 44.
- III. Claim 83, drawn to a method for treating cancer comprising administering acetominophen, classified in class 514, subclass 622.
- IV. Claim 85, drawn to a method for selectively killing cells in a mammal, classified in class 514, subclass 44.

The inventions are distinct, each from the other because of the following reasons: Inventions of Groups I, III and IV are biologically and functionally different and distinct from each other and thus one does not render the other obvious. The methods of these groups comprise steps which are not required for or present in the methods of the other groups: administration of administering a vector and acetominophen to a subject (Group I), administering acetominophen (Group III), conversion of cells to NABQI (Group IV), Thus, the operation, function and effects of these different methods are different and distinct from each other. Moreover, the end results of each of these methods differ. Therefore, the inventions of these different, distinct groups are capable of supporting separate patents.

Application/Control Number: 09/869,696

Art Unit: 1636

Inventions II and I, III and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the fact that the product of Group II can be used in the three methods disclosed shows that the product can be used in materially different processes.

Groups I and II are comprised of multiple inventions which are the products or methods drawn to different and distinct promoters and cancers which do not render obvious each other and thus are patentably distinct. If either of Groups I or II are elected, applicants must elect a single invention which is the product or method drawn to one specific promoter as disclosed in claims 47, 50, 52, 69, 72 and 74 and to one specific cancer as in claim 59 to which the claims will be restricted. The promoters and the cancers of the above groups differ functionally, structurally, and biologically from each other such that each can support a separate patentable invention.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 09/869,696

Art Unit: 1636

Page 4

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konstantina Katcheves whose telephone number is (703) 305-1999. The examiner can normally be reached on Monday through Friday 7:30 to 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel, Ph.D. can be reached on (703) 305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3014 for regular communications and (703) 305-7939 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-3388.

Konstantina Katcheves June 4, 2003

REMY YUCEL, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600